Dermapharm Holding SE (ETR:DMP)

Market Cap	1.90B +8.7%
Revenue (ttm)	1.18B +0.4%
Net Income	146.54M +36.7%
EPS	2.77 +39.0%
Shares Out	49.54M
PE Ratio	13.87
Forward PE	13.78
Dividend	0.88 (2.35%)
Ex-Dividend Date	Jun 29, 2026

Volume	23,954
Open	38.40
Previous Close	38.45
Day's Range	37.40 - 38.40
52-Week Range	32.15 - 51.90
Beta	0.85
Analysts	Buy
Price Target	51.00 (+36.0%)
Earnings Date	Nov 12, 2026

About Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 3,619
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: DMP

Financial Performance

In 2025, Dermapharm Holding SE's revenue was 1.17 billion, a decrease of -1.32% compared to the previous year's 1.18 billion. Earnings were 132.41 million, an increase of 16.37%.

Analyst Summary

According to 6 analysts, the average rating for DMP stock is "Buy." The 12-month stock price target is €51.00, which is an increase of 36.00% from the latest price.

Price Target

€51.00

(36.00% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error